U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H18N2O2
Molecular Weight 246.3049
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEFIRACETAM

SMILES

CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O

InChI

InChIKey=NGHTXZCKLWZPGK-UHFFFAOYSA-N
InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)

HIDE SMILES / InChI

Molecular Formula C14H18N2O2
Molecular Weight 246.3049
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Nefiracetam is a cyclic derivative of gamma-aminobutyric acid (GABA). It is thought to act by normalising dysfunctional acetylcholine, GABA and possibly monoamine neurotransmitter systems, but it may also facilitate N/L-type calcium channel opening. Nefiracetam has received attention as a treatment for seizures, depression, and dementia. Nefiracetam was found to be extremely testicular toxic in both rats and dogs; it was found to significantly decrease the levels of testicular testosterone leading to atrophy and malformation of sperm.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
1.97 μg/mL
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
2.08 μg/mL
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
22.6 μg/mL
1200 mg single, oral
NEFIRACETAM serum
Homo sapiens
4.02 μg/mL
200 mg single, oral
NEFIRACETAM serum
Homo sapiens
0.68 μg/mL
30 mg single, oral
NEFIRACETAM serum
Homo sapiens
10.6 μg/mL
600 mg single, oral
NEFIRACETAM serum
Homo sapiens
4.1 μg/mL
200 mg 3 times / day steady-state, oral
NEFIRACETAM serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
19.59 pg × h/mL
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
16.1 μg × h/mL
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
167 μg × h/mL
1200 mg single, oral
NEFIRACETAM serum
Homo sapiens
27.1 μg × h/mL
200 mg single, oral
NEFIRACETAM serum
Homo sapiens
5.67 μg × h/mL
30 mg single, oral
NEFIRACETAM serum
Homo sapiens
78.9 μg × h/mL
600 mg single, oral
NEFIRACETAM serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.86 h
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
4.78 h
100 mg single, oral
NEFIRACETAM serum
Homo sapiens
3.77 h
1200 mg single, oral
NEFIRACETAM serum
Homo sapiens
3.33 h
200 mg single, oral
NEFIRACETAM serum
Homo sapiens
4.43 h
30 mg single, oral
NEFIRACETAM serum
Homo sapiens
3.85 h
600 mg single, oral
NEFIRACETAM serum
Homo sapiens

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dosage lies between 8.721mg/kg and 29.072mg/kg in humans for treating the negative cognitive effects of seizures as well as treating severely depressed individuals
Route of Administration: Oral
In Vitro Use Guide
The effects of nefiracetam on GABA-induced chloride currents were studied with rat dorsal root ganglion neurons in primary culture using the whole-cell patch-clamp technique. The dose-response curve for GABA-induced currents was shifted by 16 uM to lower concentrations by 10 uM nefiracetam while the maximal response was reduced by 22.84 +/- 0.68%.
Substance Class Chemical
Record UNII
1JK12GX30N
Record Status Validated (UNII)
Record Version